News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Peptech Limited Successfully Completes Phase I Trial for PN0621
October 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
29 October 2007 Sydney, Australia: Biopharmaceutical company, Peptech Limited (ASX: PTD, AIM: PTDx) today announced the completion of the Phase I trial of its lead compound for rheumatoid arthritis PN0621.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Australia
MORE ON THIS TOPIC
Huntington’s disease
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval
April 29, 2026
·
2 min read
·
Tristan Manalac
Podcast
Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions
April 29, 2026
·
1 min read
·
Heather McKenzie
Insights
Biotech angels lean into deeper diligence and disciplined early bets
April 29, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
April 28, 2026
·
2 min read
·
Heather McKenzie
